Samsung Bioepis said on the 29th it signed a memorandum of understanding with China-based biotech R&D platform Atlatl Innovation Center to step up its global open-innovation efforts.
Atlatl Innovation Center is described as Asia’s largest biotech incubation hub linking research partnerships between biotech startups and global companies. It provides shared labs and office space, as well as contract research organization services, in major biotech clusters including Beijing, Shanghai, Singapore and Australia.
Under the agreement, Samsung Bioepis plans to screen promising biotech companies and support their early growth by helping them move into Atlatl’s facilities and carry out research activities. The company said the partnership is aimed at expanding beyond its biosimilar-focused business to identify and nurture early-stage new-drug technologies.
Samsung Bioepis said the deal is its first open-innovation project with an overseas specialized organization.
Seo Min-jeong, vice president and head of the open innovation team at Samsung Bioepis, said global cooperation is essential for biotech innovation and that the partnership will help accelerate the discovery and research of next-generation biotech technologies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.